New horizons for targeted treatment of neuroendocrine tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mangano, Alberto | - |
dc.contributor.author | Lianos, Georgios D. | - |
dc.contributor.author | Roukos, Dimitrios H. | - |
dc.contributor.author | Mason, Sam E. | - |
dc.contributor.author | Kim, Hoon Yub | - |
dc.contributor.author | Dionigi, Gianlorenzo | - |
dc.date.accessioned | 2021-09-04T05:04:43Z | - |
dc.date.available | 2021-09-04T05:04:43Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/90178 | - |
dc.description.abstract | Neuroendocrine tumors (NETs) are rare and heterogeneous tumors and there is a paucity of randomized clinical trials evaluating the different therapeutic strategies. Over recent years, some important molecular aspects have been investigated and multiple targeted therapies are currently available. One of the most promising targets for the therapy of NETs are the mTOR and angiogenic growth factor receptors. The advent of the inhibitors of the mTOR pathway, tyrosine kinase inhibitors and of somatostatin analogs have shown their efficacy in randomized clinical trials in terms of implementing clinical hormone-induced syndromes and progression-free survival of advanced NETs. This article summarizes the standard therapies and new perspectives in NET's treatment, which remains still very heterogeneous and little known entity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.subject | PANCREATIC ENDOCRINE TUMORS | - |
dc.subject | LIVER METASTASES | - |
dc.subject | MTOR PATHWAY | - |
dc.subject | EVEROLIMUS | - |
dc.subject | THERAPY | - |
dc.subject | MANAGEMENT | - |
dc.subject | SUNITINIB | - |
dc.subject | CLASSIFICATION | - |
dc.subject | EXPRESSION | - |
dc.subject | NEOPLASMS | - |
dc.title | New horizons for targeted treatment of neuroendocrine tumors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Hoon Yub | - |
dc.identifier.doi | 10.2217/fon.16.8 | - |
dc.identifier.scopusid | 2-s2.0-84961864423 | - |
dc.identifier.wosid | 000372796900009 | - |
dc.identifier.bibliographicCitation | FUTURE ONCOLOGY, v.12, no.8, pp.1059 - 1065 | - |
dc.relation.isPartOf | FUTURE ONCOLOGY | - |
dc.citation.title | FUTURE ONCOLOGY | - |
dc.citation.volume | 12 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1059 | - |
dc.citation.endPage | 1065 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | PANCREATIC ENDOCRINE TUMORS | - |
dc.subject.keywordPlus | LIVER METASTASES | - |
dc.subject.keywordPlus | MTOR PATHWAY | - |
dc.subject.keywordPlus | EVEROLIMUS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SUNITINIB | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | NEOPLASMS | - |
dc.subject.keywordAuthor | carcinoid tumors | - |
dc.subject.keywordAuthor | gastroenteropancreatic tumors | - |
dc.subject.keywordAuthor | intertumor heterogeneity | - |
dc.subject.keywordAuthor | intratumor heterogeneity | - |
dc.subject.keywordAuthor | neuroendocrine tumors | - |
dc.subject.keywordAuthor | targeted agents | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.